*Individual out-of-pocket costs may vary.

Source: Wolters Kluwer Health, Dynamic Claims, January through December 2007. Based on average monthly out-of-pocket costs for commercial and Medicare Part D patients, excluding claims by dual-eligible and low-income subsidized Medicare patients; the percentage of patients paying $29 or less per month in out-of-pocket costs ranged from 51.20% to 54.53% during 2007. Data included claims covering 4100 plans (last accessed February 20, 2008).

Approved Uses

NEXIUM 40 mg and 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for treatment of heartburn and other symptoms associated with GERD.

Important Safety Information

NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer.

As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time.

Concomitant use of atazanavir and PPIs is not recommended because the plasma concentrations of atazanavir are expected to substantially decrease and thereby reduce its therapeutic effect.

NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information.
Please see accompanying full Prescribing Information.

Click here for Complete Prescribing Information

Click here to visit the Nexium Web site

Reference: 1. Data on file, DA-NEX-99: Wolters Kluwer Health, Dynamic Claims, January through December 2007.

NEXIUM and the color purple as applied to the capsule are registered trademarks of the AstraZeneca group of companies. © 2008 AstraZeneca LP. All rights reserved.          261343          4/08